Tags

Type your tag names separated by a space and hit enter

Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
BJU Int. 2008 Jul; 102(2):198-202.BI

Abstract

OBJECTIVE

To evaluate the factors affecting outcome and the pathological findings in patients who had retroperitoneal lymph node dissection (pcRPLND) after chemotherapy with elevated tumour markers, as such patients have an unfavourable prognosis, with further salvage chemotherapy being the usual treatment of choice.

PATIENTS AND METHODS

Information on the preoperative treatment, tumour markers, histopathology and outcome data of the patients who had pcRPLND were extracted from the hospital databases. Survival was analysed using the Kaplan-Meier method and multivariate analysis with Cox regression model.

RESULTS

In all, 358 patients had pcRPLND between September 1992 and April 2006, by one surgeon. In 48 patients the tumour markers were elevated at the time of surgery, they were on a 'rising trend' in 26 (54%) and 'downward or stable' trend in 22 (46%). The overall incidence of active germ cell tumour, differentiated teratoma and necrosis in the resected specimens was 58%, 25% and 17%, respectively. The median follow-up was 51.5 months and the overall 5-year survival was 69%. The favourable prognostic factors assessed by univariate analysis were elevation of alpha-fetoprotein alone, complete resection of residual disease, histological finding of differentiated teratoma in the resected tissues and normalization of tumour markers after pcRPLND. By multivariate analysis the only statistically significant independent survival factor was the normalization of the tumour markers after pcRPLND.

CONCLUSION

For selected patients with elevated tumour markers after chemotherapy, RPLND can offer a significant chance of cure with no need for further chemotherapy. The patients most likely to benefit are those with elevations of alpha-fetoprotein alone. In this group, pcRPLND can offer the prospect of long-term survival and should be considered in the management of selected patients.

Authors+Show Affiliations

Charing Cross Hospital, London, UK. ongta2005@yahoo.co.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18294302

Citation

Ong, Teng A., et al. "Retroperitoneal Lymph Node Dissection After Chemotherapy in Patients With Elevated Tumour Markers: Indications, Histopathology and Outcome." BJU International, vol. 102, no. 2, 2008, pp. 198-202.
Ong TA, Winkler MH, Savage PM, et al. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU Int. 2008;102(2):198-202.
Ong, T. A., Winkler, M. H., Savage, P. M., Seckl, M. J., & Christmas, T. J. (2008). Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU International, 102(2), 198-202. https://doi.org/10.1111/j.1464-410X.2008.07533.x
Ong TA, et al. Retroperitoneal Lymph Node Dissection After Chemotherapy in Patients With Elevated Tumour Markers: Indications, Histopathology and Outcome. BJU Int. 2008;102(2):198-202. PubMed PMID: 18294302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. AU - Ong,Teng A, AU - Winkler,Mathias H, AU - Savage,Philip M, AU - Seckl,Michael J, AU - Christmas,Timothy J, Y1 - 2008/07/01/ PY - 2008/2/26/pubmed PY - 2008/7/25/medline PY - 2008/2/26/entrez SP - 198 EP - 202 JF - BJU international JO - BJU Int. VL - 102 IS - 2 N2 - OBJECTIVE: To evaluate the factors affecting outcome and the pathological findings in patients who had retroperitoneal lymph node dissection (pcRPLND) after chemotherapy with elevated tumour markers, as such patients have an unfavourable prognosis, with further salvage chemotherapy being the usual treatment of choice. PATIENTS AND METHODS: Information on the preoperative treatment, tumour markers, histopathology and outcome data of the patients who had pcRPLND were extracted from the hospital databases. Survival was analysed using the Kaplan-Meier method and multivariate analysis with Cox regression model. RESULTS: In all, 358 patients had pcRPLND between September 1992 and April 2006, by one surgeon. In 48 patients the tumour markers were elevated at the time of surgery, they were on a 'rising trend' in 26 (54%) and 'downward or stable' trend in 22 (46%). The overall incidence of active germ cell tumour, differentiated teratoma and necrosis in the resected specimens was 58%, 25% and 17%, respectively. The median follow-up was 51.5 months and the overall 5-year survival was 69%. The favourable prognostic factors assessed by univariate analysis were elevation of alpha-fetoprotein alone, complete resection of residual disease, histological finding of differentiated teratoma in the resected tissues and normalization of tumour markers after pcRPLND. By multivariate analysis the only statistically significant independent survival factor was the normalization of the tumour markers after pcRPLND. CONCLUSION: For selected patients with elevated tumour markers after chemotherapy, RPLND can offer a significant chance of cure with no need for further chemotherapy. The patients most likely to benefit are those with elevations of alpha-fetoprotein alone. In this group, pcRPLND can offer the prospect of long-term survival and should be considered in the management of selected patients. SN - 1464-410X UR - https://www.unboundmedicine.com/medline/citation/18294302/Retroperitoneal_lymph_node_dissection_after_chemotherapy_in_patients_with_elevated_tumour_markers:_indications_histopathology_and_outcome_ L2 - https://doi.org/10.1111/j.1464-410X.2008.07533.x DB - PRIME DP - Unbound Medicine ER -